Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | HRH2 | P25021 | 8/20 | 0.45 |
| ▸ | HRH1 | P35367 | 8/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GPR4 | P46093 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7246309 | 1.00 | GPR119 (0.49) | GPR119EPHX2HRH2HRH1MAOB | |
| SCHEMBL7248254 | 0.96 | GPR119 (0.49) | GPR119EPHX2HRH2HRH1MAOB | |
| SCHEMBL7248251 | 0.96 | GPR119 (0.49) | GPR119EPHX2HRH2HRH1MAOB | |
| SCHEMBL7251804 | 0.84 | HRH2 (0.55) | EPHX2HRH2HRH1 | |
| SCHEMBL7251887 | 0.80 | HRH2 (0.52) | GPR119EPHX2HRH2HRH1HRH3 | |
| SCHEMBL3587105 | 0.78 | GPR119 (0.52) | GPR119EPHX2MAOBHRH3 | |
| SCHEMBL18910879 | 0.77 | EPHX2 (0.59) | EPHX2HRH2HRH1HRH3 | |
| SCHEMBL13320335 | 0.77 | EPHX2 (0.52) | EPHX2HRH2HRH1HRH3 | |
| SCHEMBL7246082 | 0.77 | GPR119 (0.51) | GPR119EPHX2HRH2HRH1HRH3 | |
| SCHEMBL214957 | 0.77 | EPHX2 (0.50) | GPR119EPHX2HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | HRH4, HRH2, HRH3 | GPR119 534/4885EPHX2 840/4885HRH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.